Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Bacillus Calmette-Guérin (BCG) is used as first-line intravesical therapy following tumor resection of non-muscle-invasive bladder cancer. Primary producers of BCG announced shortages within the last decade, leading to a worldwide shortage. We review the literature examining the BCG shortage and propose solutions to cope with this problem.

Original publication

DOI

10.1016/j.euf.2018.06.018

Type

Journal article

Journal

Eur Urol Focus

Publication Date

07/2018

Volume

4

Pages

481 - 484

Keywords

Bacillus Calmette-Guérin, Bladder cancer, Shortage, Adjuvants, Immunologic, Administration, Intravesical, BCG Vaccine, Drug Utilization, Drug and Narcotic Control, Humans, Neoplasm Invasiveness, Urinary Bladder Neoplasms